IL-2
Interleukin-2 (IL-2) is a key cytokine regulating T cell proliferation, differentiation, and survival[1]. Mechanistically, IL-2 signals through the heterotrimeric IL-2 receptor complex, activating the JAK1/3-STAT5 pathway to induce transcription of genes critical for T cell expansion and function[1]. In disease models, IL-2 has been shown to drive regulatory T cell (Treg) expansion, contributing to immune homeostasis and suppression of autoimmunity, while its dysregulation is implicated in cancer and chronic inflammatory conditions[1]. Compared with related γ-chain cytokines, IL-2 exhibits unique receptor specificity and distinct downstream signaling kinetics, leading to selective activation of Tregs versus effector T cells[1]. Experimentally, IL-2 stimulation induces expression and unconventional secretion of IL-32β from T cells, highlighting a functional crosstalk between IL-2 signaling and proinflammatory cytokine networks[1]. Agonists and inhibitors of IL-2 or its receptor have been utilized to manipulate immune responses, providing platforms for preclinical models of autoimmunity, cancer immunotherapy, and T cell functional studies[1]. Therefore, IL-2 serves as both a central immunoregulatory factor and a practical tool for experimental modulation of T cell-mediated immunity[1].
-
IL-2 Related Products (116)
Related Products (116)
-
Recombinant Proteins (22)
-
PROTAC HPK1 Degrader-8
0 ImagesCat. No.: HY-184230CAS No.: 3120899-50-2PROTAC HPK1 Degrader-8 is a HPK1 PROTAC degrader with a DC50 of 1-10 nM. PROTAC HPK1 Degrader-8 promotes HPK1 ubiquitination and degradation. PROTAC HPK1 Degrader-8 induces IL-2 production, with an EC50 of 3 nM. PROTAC HPK1 Degrader-8 can be used in research related to hematologic malignancies and solid tumors.
-
PTPN22-IN-3
0 ImagesCat. No.: HY-184931PTPN22-IN-3 is a potent, selective, and orally active inhibitor of PTPN22 with an IC50 of 0.49 μM and a Ki of 0.28 μM. PTPN22-IN-3 exhibits over 14-fold selectivity against a broad panel of PTPs and shows no significant inhibition against SRC/CSK kinases or IDO1/Arginase metalloenzymes. PTPN22-IN-3 enhances TCR signaling, increases IL-2 expression and secretion, and promotes mouse splenic T cell proliferation. In immune-competent C57BL/6J mice, PTPN22-IN-3 suppresses MC38 syngeneic tumor growth and synergizes with Pembrolizumab (anti-PD-1) (HY-P9902A) therapy. PTPN22-IN-3 can be used for the study of colorectal cancer and other solid tumors responsive to T cell-mediated anti-tumor immunity.
-
RS-0481
0 ImagesCat. No.: HY-123221CAS No.: 134931-74-1RS-0481 is an orally active lymphocyte population function restorer. RS-0481 enhances IL-2 production activity. RS-0481 can re-establish the function of certain lymphoid cell populations impaired by the presence of a growing tumor in an animal. RS-0481 markedly augments the tumor-specific cytotoxic T lymphocytes, TDTH, and the nonspecific lymphokine-activated-killer-cell-like cell responses.
-
IKZF2-degrader 5
0 ImagesCat. No.: HY-182945IKZF2-degrader 5 is a highly efficient, highly selective, rapidly acting, and orally active IKZF2 molecular glue degrader. IKZF2-degrader 5 induces IKZF2 degradation via the Cullin-CRBN-dependent pathway. IKZF2-degrader 5 promotes the production of pro-inflammatory IL-2. IKZF2-degrader 5 attenuates the immunosuppressive function of regulatory T cells (Tregs). IKZF2-degrader 5 triggers rapid, significant, and sustained IKZF2 degradation in the spleen and thymus of mice. IKZF2-degrader 5 inhibits tumor growth. IKZF2-degrader 5 can be used for the research of B16F melanoma.
-
HPN601
0 ImagesCat. No.: HY-P992370HPN601 is a monoclonal antibody targeting CD326/EPCAM, as well as a protease-activated EpCAM-targeted T cell engager. HPN601 binds to EPCAM, CD3e and albumin, and induces T cell-mediated tumor cell killing. HPN601 significantly reduces the release levels of IFN-γ, IL-2, IL-6, and IL-10. HPN601 can be used for relevant research on cancers such as breast cancer and gastric cancer.
-
Myelopeptide-2
0 ImagesCat. No.: HY-P3736CAS No.: 137833-31-9Synonyms: MP-2Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research.
-
CD28-IN-1
0 ImagesCat. No.: HY-175780CAS No.: 1465291-19-3CD28-IN-1 (Compound 19MS-5) is a CD28 inhibitor with a KD of 12.48 μM. CD28-IN-1 has a superior binding capacity to CD28 and potently inhibits CD28-B7 interactions. CD28-IN-1 inhibits CD28-driven immune activation and suppresses cytokine (IFN-γ, IL-2 and TNF-α) production in primary human T cells co-cultured with tumor spheroids and human epithelial tissues. CD28-IN-1 can be used for tumor immunity research.
-
REGN-10597
0 ImagesCat. No.: HY-P992161REGN-10597, composed of an anti-huPD-1-targeting antibody and IL2Ra-IL2 moiety, is a PD-1-dependent IL-2 agonist. REGN-10597 binds PD-1 to deliver masked native IL-2 to PD-1+ T cells, engaging trimeric IL-2 receptors to activate downstream signaling. REGN-10597 can be used for the research on melanoma, prostate cancer, colorectal cancer, and ovarian cancer.
-
5-Androstenetriol
0 Images5-Androstenetriol is a systemic radiation protector that can boost the host's immunity, leading to increased resistance to infections. 5-Androstenetriol can raise levels of IL-2, IL-3, and IFN, while countering the immunosuppressive effects of Hydrocortisone (HY-N0583).
-
23ME-00610
0 ImagesCat. No.: HY-P99216223ME-00610 is a humanized effector-function-null IgG1 antibody targeting CD200R1, with a Kd of <0.1 nM for hCD200R1. 23ME-00610 blocks the binding of CD200 to CD200R1 and inhibits the recruitment of the downstream adaptor protein DOK2 to CD200R1. 23ME-00610 restores IL-2 production suppressed by CD200. 23ME-00610 induces cytokine production in cells. 23ME-00610 enhances cell-mediated tumor cell killing in vitro. 23ME-00610 can be used for melanoma research.
-
TCR-IN-1
0 ImagesCat. No.: HY-180608CAS No.: 2375042-31-0
-
HPK1-IN-69
0 ImagesCat. No.: HY-182238CAS No.: 3095423-83-6HPK1-IN-69 is an orally active HPK1 inhibitor with an IC50 of 1.7 nM. HPK1-IN-69 inhibits the HPK1-mediated TCR signaling pathway, reduces the phosphorylation level of SLP76, and promotes the release of IL-2. HPK1-IN-69 exhibits in vivo anti-tumor activity in mouse models. HPK1-IN-69 can be used for the research of colorectal cancer and MC38 syngeneic tumors.
-
NFAT-133
0 ImagesCat. No.: HY-N16431CAS No.: 165133-85-7NFAT-133 is an aromatic polyketide with immunosuppressive and antidiabetic activity. NFAT-133 activates the AMPK pathway, promoting glucose uptake in L6 muscle fibers, thereby resisting diabetes. NFAT-133 inhibits the transcriptional activity of activated T-cell nuclear factor (NFAT), thereby suppressing the expression of IL-2 and the proliferation of T cells, demonstrating an immunosuppressive effect. NFAT-133 does not exhibit antibacterial activity or cytotoxicity, but it can weaken the production of NO in RAW264.7 cells induced by Lipopolysaccharide (LPS) (HY-D1056).
-
M802
0 ImagesCat. No.: HY-P992401M802 is an anti-HER2/CD3 bispecific antibody, with a Kd of 0.578 nM for human HER2 and a Kd of 71.2 nM for human CD3. M802 inhibits the PI3K/AKT and MAPK signaling pathways, suppresses tumor cell proliferation, activates caspase-3, and promotes tumor cell apoptosis (apoptosis). M802 recruits and activates CD3-positive immune cells, mediates cytotoxicity against HER2-positive tumor cells, and induces immune cells to secrete IFN-γ, TNF-α, IL-2 and IL-6. M802 exhibits anti-tumor efficacy in mice with gastric cancer xenografts. M802 can be used in research related to HER2-positive breast cancer, HER2-positive gastric cancer and other cancers. The recommended isotype control is human IgG1 kappa (HY-P99001).
-
IBI-325
0 ImagesCat. No.: HY-P991634IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.
-
HPK1-IN-65
0 ImagesCat. No.: HY-179338HPK1-IN-65 is a selective and orally active HPK1 inhibitor with an IC50 value of < 5 nM. HPK1-IN-65 inhibits HPK1 kinase activity and displays 1257-fold selectivity over the MAP4K kinase family member GLK. HPK1-IN-65 exhibits an IC50 of 92.3 nM for inhibiting pSLP76 phosphorylation. HPK1-IN-65 demonstrates an EC50 of 398 nM for stimulating IL-2 production. HPK1-IN-65 inhibits TCR-induced phosphorylation of SLP76 at Ser376 in a dose-dependent manner. HPK1-IN-65 can be further utilized for colorectal cancer research.
-
GNE-7056
0 ImagesCat. No.: HY-189477CAS No.: 1557236-81-3GNE-7056 is an orally active interleukin-2-inducible T-cell kinase (ITK) inhibitor with a Ki of 0.2 nM against human kinase, and exhibits high selectivity over LCK kinase. GNE-7056 inhibits PLCγ-1 phosphorylation, suppresses the production of IL-2, IL-4, IL-13 and TH2 cytokines, reduces CD4+ T-cell proliferation, and inhibits activation-induced cell death of CD4+ T cells by decreasing the abundance of FasL. GNE-7056 can be used in asthma-related research.
-
Immuno modulator-1
0 ImagesCat. No.: HY-153952CAS No.: 2757469-20-6Immuno modulator-1 (compound 22) inhibits TNFα and IL-2 secretion in human peripheral blood mononuclear cells (hPBMC), with IC50 values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM.
-
PROTAC IRAK4 degrader-14
0 ImagesCat. No.: HY-181708CAS No.: 3113890-51-7
-
DF6002
0 ImagesCat. No.: HY-P991436Synonyms: BMS-986415
